Fortrea Holdings FTRE
Management team
Background
Mr. Thakral has served as our Chief Executive Officer and a member of our Board of Directors since August 2025. Mr. Thakral has more than 25 years of experience in the CRO, pharmaceutical, and biotech industries as a general manager, management consultant, commercial leader and entrepreneur. He previously served as Co-Founder and Chief Executive Officer of Launch Therapeutics since its founding in March 2022. From July 2016 to February 2022, Mr. Thakral served in increasing levels of seniority at PPD, Inc. (PPD), from Global Head of PPD Biotech to Chief Commercial Officer and Executive Vice President of Peri- and Post-Approval Services at PPD. Before PPD, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group from March 2014 to June 2016 and served as a consultant at McKinsey & Company from August 2006 to March 2014, where he was an associate principal in the healthcare practice, counselling senior management and CEOs of global pharmaceutical and biotechnology companies. Mr. Thakral currently serves on the board of directors of Orsini Specialty Pharmacy, a leader in pharmacy solutions for rare disease and complex therapy programs and earned his Bachelor of Science and Master of Science in Engineering in Biomedical Engineering from Johns Hopkins University and his Master of Business Administration from the Wharton School at the University of Pennsylvania.
Background
Mark Morais has served as our Chief Operating Officer and President, Clinical Services, since the Spin. Previously, Mr. Morais served as President of Clinical Services and Commercial Solutions, within the Labcorp Drug Development segment, since September 2020 and Chief Operating Officer and President of Clinical Development and Commercialization Services, since October 2022. Prior to September 2020, Mr. Morais served as Senior Vice President Strategic Deal Development, Enterprise Client Solutions and Alliance Management at Covance, Labcorp's drug development company, from May 2018 to September 2020 and from June 2017 to May 2018 he served as Covance's Vice President of Strategic Deal Development and Pricing. Prior to Covance, Mr. Morais served in various positions of increasing responsibility at Quintiles from April 2001 to 2017. Mr. Morais earned his Bachelor of Science degree from North Carolina State University.
Background
Mr. Neupert has served as a director since June 2023. Mr. Neupert served as an Operating Partner at Health Evolution Partners, a private equity fund, from February 2012 to July 2014. Prior to joining Health Evolution Partners, Mr. Neupert served as Corporate Vice President, Health Solutions Group at Microsoft from August 2005 to January 2012, and as the Chief Executive Officer and Chairman of the board of directors of drugstore.com, which he joined in July 1998. Prior to drugstore.com, Mr. Neupert was Corporate Vice President for News and Publishing at Microsoft, where he created and led MSNBC.com and MSNBC Cable and managed Microsoft's other online publishing entities including Slate.com. Since 2013, Mr. Neupert has served as a director of Labcorp, a public, global life sciences company, and as a director of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company. Mr. Neupert previously served as a member of the board of directors of NextGen Healthcare, Inc., a public software company, and several private companies. Mr. Neupert served as a member of the Board of Trustees of Fred Hutchinson Cancer Research Center from June 2007 to June 2020. Mr. Neupert earned his Bachelor of Arts in Philosophy from Colorado College and his Master of Business Administration from the Tuck School of Business at Dartmouth College.
Background
Ms. Russell has served as a director since March 2025. She was appointed to serve on the board of Modivcare, a technology-enabled healthcare services company, in February 2025, and has also served on the boards of eHealth, Inc., a leading online health insurance marketplace, since July 2021, and Kadant Inc., a global supplier of high-value engineered systems used in process industries worldwide, since January 2019. Her previous board experience in the healthcare sector includes Tivity Health Inc., a leading provider of healthy living, fitness and social engagement solutions, DeVilbiss Healthcare LLC, a company that designs, manufactures and markets respiratory medical products, DynaVox Inc., a communications device manufacturer, and 21st Century Oncology Inc., a provider of state-of-the-art radiation therapy and integrated cancer treatments. Previously, Ms. Russell served as an industry advisor of Starboard Value Acquisition Corporation, a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, from August 2020 until August 2021. Ms. Russell spent 16 years as a principal of Vestar Capital Partners, L.P., a leading private equity firm specializing in management buyouts, recapitalizations, and growth equity investments. Ms. Russell is currently chair of the board of St. Thomas Aquinas Catholic School, where she has served since June 2018, and chair of the advisory board of McIntire School of Commerce and member of advisory board of the Jefferson Scholars Foundation at the University of Virginia, where she has served since June 2016 and April 2008, respectively. Ms. Russell earned her Bachelor of Science in Commerce, with a concentration in Accounting, from the McIntire School of Commerce at the University of Virginia and her Master of Business Administration from Harvard Business School.
Background
Dr. Ray has served as a director since June 2023. Dr. Ray is a physician researcher and advisor to life science companies. Dr. Ray has over 25 years of biomedical research and pharmaceutical industry experience. From March 2022 until December 2022, Dr. Ray served as the Chief Patient Officer at Biohaven Pharmaceuticals, a biopharmaceutical company. From 2017 until January 2021, Dr. Ray served as the Global President, Head of R&D and Medical, overseeing all aspects of R&D worldwide for the Essential Health and later Upjohn divisions at Pfizer, a biopharmaceutical company. Previously, from 2009-2017, Dr. Ray served in positions of increasing responsibility including as the Chief Medical Officer and as the Chief Safety Officer for global pharmaceuticals at Johnson & Johnson, a healthcare company. Dr. Ray earned his degrees in Immunology and in Medicine at Edinburgh University, and his Master of Business Administration from the Tuck School of Business at Dartmouth College. Dr. Ray is a Visiting Professor of Practice at the Faculty of Medical Sciences of Newcastle University, UK, and serves on the Board of Trustees at The Hastings Center for Bioethics. Since 2022, Dr. Ray has served as a director of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company.
Background
Mr. Smith, 60, has over 25 years of pharmaceutical industry experience and has served on the Board since 2023. Mr. Smith served as Executive Vice President and Chief Financial Officer for Charles River Laboratories International, Inc., an American pre-clinical contract research organization supporting the global pharmaceutical industry. Mr. Smith joined Charles River in April 2014 through their acquisition of the Galapagos Services Division, which was carved out from its parent company Galapagos NV, a Belgian pharmaceutical research company. Mr. Smith served as the Chief Executive Officer for that division and, on its acquisition, continued to manage its operation as Corporate Vice President at Charles River. In October that year, Mr. Smith was promoted to Corporate Senior Vice President with responsibilities for all Discovery Services at Charles River. In the following February, he was nominated as the successor to the incumbent Chief Financial Officer, formally taking the helm in August 2015, a post Mr. Smith held until his retirement in May 2022. During Mr. Smith's tenure as Chief Financial Officer, Charles River entered the S&P 500 in May 2021. Previously, Mr. Smith also served as Chief Financial Officer at Cambridge University Hospitals in the United Kingdom and Galapagos NV. He held management positions at AstraZeneca in the Netherlands, Hungary, Sweden and the U.K. and held a variety of leadership roles, including in the R&D division where he helped determine which molecules progressed through the pipeline. Mr. Smith trained as a Chartered Accountant in the U.K., with what is now called PricewaterhouseCoopers, before relocating with the firm to Dubai. Mr. Smith earned his Bachelor of Sciences Honors degree in Molecular Biophysics at the University of Leeds, U.K. On July 27, 2026, the Board of Directors of the Company appointed David Smith, a current director on the Board, to act as Interim Chief Financial Officer and principal financial officer (Interim CFO). On 09 September 2026, David Smith stepped down as the Interim Chief Financial Officer. He remains as a member of the Board of Directors.
Background
Ms. Sanders has served as a director since May 2024. Ms. Sanders is an accomplished biopharmaceutical and public-sector leader with deep expertise in quality, compliance, operations, and large-scale organizational transformation. She has held senior leadership roles at Biogen, Inc., including Vice President of Multiple Sclerosis Franchise Product Operations-where she led global operational strategies, life cycle management, and regulatory execution for therapies and Vice President of Manufacturing & General Manager of the RTP, NC site, overseeing 1,200 employees, biologics and small-molecule operations, major capital expansions, and global regulatory approvals. Her executive experience extends to state government, serving as North Carolina's Secretary of Commerce from February 2021 to January 2025 and Secretary of Administration from January 2017 to February 2021, where she led statewide economic development, workforce strategy, and government operations. Since February 2022, she has served on the board of BioCryst Pharmaceuticals, Inc., a global public biotechnology company, where she is a member of the science committee and chairperson of the compensation committee. Ms. Sanders previously served as a member of the boards of directors of Novan, Inc. from 2017 to April 2024 and Radius Health, Inc. from 2021 to August 2022. Ms. Sanders earned a Bachelor of Science in Biochemistry from North Carolina State University and a Master's in Health Administration from Pfeiffer University. She has also pursued continued executive development through Stanford University's Directors' Consortium.
Background
Mr. Pesicka has served as a director since June 2023. Since March 2019, Mr. Pesicka has served as President and Chief Executive Officer, as well as on the board of directors, of Owens & Minor, Inc., a global healthcare solutions company. From January 2016 until March 2019, Mr. Pesicka was an independent consultant and advisor in the healthcare, life science and distribution industries. From January 2000 until April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., an American supplier of scientific instrumentation, reagents and consumables and software services, including Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW Inc., an aerospace company in its finance department and three years with PricewaterhouseCoopers as an auditor. Mr. Pesicka earned his Master of Business Administration from Weatherhead School of Management at Case Western Reserve University and a Bachelor of Arts in Business Administration and Management from Muskingum College. Since 2019, Mr. Pesicka has served as a director of Owens & Minor, Inc., a global healthcare logistics and supply chain management company.
Background
Mr. Sharbaugh was appointed to our Board of Directors on September 22, 2025. Mr. Sharbaugh brings extensive experience in the biopharmaceutical and life sciences industry, having served in executive and board roles during his more than three decades in the pharmaceutical industry. Mr. Sharbaugh currently serves as chairman of the board of Ora Clinical, a specialty ophthalmology contract research organization, as well as a member of the board of directors of Launch Therapeutics, Inc., a late-stage pharmaceutical development company. In addition, Mr. Sharbaugh previously served as a member of the board of directors of BioCareSD, Inc., a drug distribution company, and Alcami Corporation, a contract distribution and manufacturing company. His previous executive experience includes serving as chief operating officer for PPD, a CRO, from 2007 to 2021. Mr. Sharbaugh earned his B.S from the U.S. Military Academy at West Point, a M.S. in the Management of Technology from the Wharton School and the School of Engineering at the University of Pennsylvania, a M.S in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy, and a M.A. in International Relations from Boston University School of Arts and Sciences.
Background
Effective October 5, 2026, Fortrea Holdings Inc. appointed Carrie Russell as its Chief Accounting Officer. Ms. Russell has served as the Company's interim Chief Accounting Officer and interim principal accounting officer since August 7, 2026, while continuing in her role as Vice President of Accounting. She will continue to serve as the Company's principal accounting office. Ms. Russell currently serves as the Company's Vice President of Accounting, a position she has held since August 2024. As Vice President of Accounting, Ms. Russell is responsible for the Company's accounting function, including technical accounting, accounting policy, financial close and consolidation, internal controls over financial reporting, and external financial reporting. Prior to joining the Company, Ms. Russell spent nearly 17 years with PricewaterhouseCoopers LLP (PwC'), most recently serving as a Trust Solutions Audit Director within the Health Industries practice. Her tenure at PwC included two years in PwC's National Office SEC Services group, where she advised registrants and engagement teams on SEC reporting requirements, financial reporting matters, and the application of U.S. GAAP and SEC regulations. Ms. Russell is a Certified Public Accountant and received a Bachelor of Science in Business Administration and a Master of Accountancy from the University of North Carolina at Chapel Hill. She currently serves on the Board of Directors of the North Carolina Museum of Art Foundation.
Background
The Company's Board of Directors has appointed Jason F. Knoblauch, 45, as CFO and principal financial officer, effective July 6, 2026. Mr. Knoblauch has over 20 years of experience in finance, capital markets, and strategic operations across the life sciences, clinical research, and professional services industries. From August 2023 to June 2026, Mr. Knoblauch served in multiple roles at Clario, a leading provider of digital endpoint data solutions, including as Executive Vice President and Chief Financial Officer. Prior to Clario, Mr. Knoblauch served as Senior Vice President and Chief Financial Officer of Curia (formerly Albany Molecular Research, Inc.), a global contract research, development and manufacturing organization, from April 2020 to August 2023. From April 2013 to March 2020, Mr. Knoblauch served in a variety of finance roles of increasing responsibility at Pharmaceutical Product Development (PPD), including Senior Vice President, Business and Commercial Finance, Interim Chief Financial Officer, and Head of Corporate Finance/FP&A. Earlier in his career, Mr. Knoblauch worked in transaction advisory services at PricewaterhouseCoopers from 2006 to 2013, and began his career in audit at Ernst & Young from 2003 to 2006. Mr. Knoblauch is a member of the Board of Directors of Surgical Information Systems, a provider of software solutions and services for ambulatory surgery centers. Mr. Knoblauch earned a Master of Science in Accounting from the University of Virginia and a Bachelor of Science in Business Administration in Finance and Economics from Creighton University. Jason Knoblauch, who was appointed as the Company's Chief Financial Officer effective July 6, 2026, was placed on a paid leave of absence. On September 9, 2026, the Board of Directors of Fortrea Holdings, Inc. reinstated Jason Knoblauch as Chief Financial Officer and designated Mr. Knoblauch as principal financial officer of the Company.
From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.
No comments yet — be the first to weigh in on FTRE.
Sign in to join the discussion.